Psoriasis
We recommend
Bimekizumab in the treatment of moderate to severe hidradenitis suppurativa – another approved indication for this biological agent
In May, the primary results of the BE HEARD I and II studies evaluating the efficacy and safety of the IL-17A and IL-17F inhibitor bimekizumab in the treatment of moderate to severe hidradenitis suppurativa (HS) in adults were published in The Lancet. This is the first publication of the results of these Phase III studies. Based on these findings, the European Medicines Agency (EMA) approved bimekizumab (which is currently approved for the treatment of plaque psoriasis, psoriatic arthritis, and axial spondyloarthritis) for the treatment…
Expert Consensus on the Use of Bimekizumab in the Treatment of Plaque Psoriasis and Psoriatic Arthritis
The expert consensus published in February 2024 offers guidance on the use of bimekizumab in the…
Bimekizumab in 3rd Line Biological Treatment After Risankizumab Failure – Case Study
The possibilities of biological therapy for severe forms of psoriasis are very broad today. Achieving...
Articles on this topic
What Results Does Bimekizumab Achieve in Patients with PsA After 3 Years of Treatment?
Fresh findings from the BE ACTIVE study were published this year in the journal Rheumatology,…
Mental Health as an Overlooked Topic in Patients with Psoriasis
Psoriasis is an inflammatory, non-infectious disease primarily affecting the skin, and…
AAD 2023: Efficacy of Bimekizumab in the Treatment of Hidradenitis Suppurativa
At the latest annual congress of the American Academy of Dermatology (AAD), held March 17-22,…
Bimekizumab in the Treatment of Psoriasis After Failure of (Not Only) Anti-IL-17A Antibodies – Case Reports
German authors last year described the first 2 cases of patients with psoriasis in whom…
Bimekizumab vs. Adalimumab in the Treatment of Moderate to Severe Plaque Psoriasis
Bimekizumab is a humanized IgG1 monoclonal antibody that selectively inhibits interleukins 17A…
Safety and Efficacy of Bimekizumab Self-Administration in Psoriasis Patients
Patient adherence to regular administration of biologic therapy is crucial for its…
Efficacy and Safety of Bimekizumab in the Treatment of Moderate to Severe Plaque Psoriasis - BE READY Study Results
The interleukin 17 (IL-17) family represents a group of pro-inflammatory cytokines that play a…
New Drug in the Biologic Therapy Arsenal for Plaque Psoriasis
Bimekizumab shows promising effects in clinical studies with psoriasis patients. Let's take a…
Bimekizumab – Higher Chance of Complete Skin Healing in Moderate to Severe Psoriasis?
In August 2021, the European Medicines Agency (EMA) approved bimekizumab (Bimzelx LP) as the…
Most read on this topic
- Bimekizumab – Higher Chance of Complete Skin Healing in Moderate to Severe Psoriasis?
- Mental Health as an Overlooked Topic in Patients with Psoriasis
- Bimekizumab in 3rd Line Biological Treatment After Risankizumab Failure – Case Study
- AAD 2023: Efficacy of Bimekizumab in the Treatment of Hidradenitis Suppurativa
- What Results Does Bimekizumab Achieve in Patients with PsA After 3 Years of Treatment?